2Zhong Xi Yi Jie He Xue Bao Chinese Association of Integrative Medicine, Liver Disease Committee.肝纤维化中西医结合诊疗指南[J].中西医结合学报,2006,4(6):551-555. 被引量：28
3Holmes JA, Nguyen T,Ratnam D, et al. IL28B genotype is not use-ful for predicting treatment outcome in Asian chronic hepatitis B pa-tients treated with pegylated interferon - alpha [ J ]. J GastroenterolHepatol,2013,28 (5): 861 -866.
4Tseng TC,Yu ML, Liu CJ, et al. Effect of host and viral factors onhepatitis B e antigen-positive chronic hepatitis B patients receivingpegylated interferon - alpha - 2a therapy [j]. Antivir Ther, 2011,16(5):629-637.
5Wu X, Xin Z,Zhu X,et al. Evaluation of susceptibility locus for re-sponse to interferon - alpha based therapy in chronic hepatitis B pa-tients in Chinese[J]. Antiviral Res,2012,93(2) :297-300.
6Zhang Q, Lapaius M, Asselah T, et al. IFNL3 (IL28B) polymor-phism does not predict long-term response to interferon therapy inHBeAg - positive chronic hepatitis B patients [J]. J Viral Hepat,2014,21(7):525-532.
7Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and theirclass II cytokine receptor IL-28R[j]. Nat Immunol, 2003,4(1):63-68.
